Tuberculosis (TB) was announced as a global emergency in 1993. There was an alarming
counter attack of TB worldwide. However, when it was known that TB can be cured …

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Tuberculosis—the world's leading cause of death by infectious disease—is increasingly
resistant to current first-line antibiotics. The bacterium Mycobacterium tuberculosis (which …

Magnesium oxide nanoparticle (nMgO) is a light metal based antimicrobial nanoparticle that
can be metabolized and fully resorbed in the body. To take advantage of the antimicrobial …

New therapeutic strategies are needed to combat the tuberculosis pandemic and the spread
of multidrug-resistant (MDR) and extensively drug-resistant (XDR) forms of the disease …

Natural product drug discovery has regained interest due to low production costs, structural
diversity, and multiple uses of active compounds to treat various diseases. Attention has …

Tuberculosis (TB) is more prevalent in the world today than at any other time in human
history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse …

Persistent infections involving slow-growing or non-growing bacteria are hard to treat with
antibiotics that target biosynthetic processes in growing cells. Consequently, there is a need …

Drug-resistant tuberculosis (DR-TB), including multi-and extensively drug-resistant TB, is
posing a significant challenge to effective treatment and TB control worldwide. New progress …

Treatment of tuberculosis, a complex granulomatous disease, requires long-term multidrug
therapy to overcome tolerance, an epigenetic drug resistance that is widely attributed to …